United Therapeutics Corp (FRA:UTH)
€ 245.3 4.6 (1.91%) Market Cap: 10.88 Bil Enterprise Value: 8.92 Bil PE Ratio: 12.50 PB Ratio: 2.19 GF Score: 89/100

United Therapeutics Corp at JPMorgan Healthcare Conference Transcript

Jan 13, 2020 / 09:30PM GMT
Release Date Price: €77 (-3.14%)
Jessica Macomber Fye
JP Morgan Chase & Co, Research Division - Analyst

Good afternoon, everyone. My name is Jess Fye. I'm one of the biotech analysts at JPMorgan. We're continuing the 2020 Healthcare Conference today with United Therapeutics. Quick housekeeping note, we're going to do a Q&A session right after this just down the hall in the Sussex Room. You can follow me there.

But with that, I'll turn it over to the company's CEO, Martine Rothblatt.

Martine A. Rothblatt
United Therapeutics Corporation - Founder, Chairman & CEO

Thank you, Jess. Very glad to be here at the JPMorgan 2020 Healthcare Conference. I'm joined today by my colleagues, Michael Benkowitz, President and Chief Operating Officer, to my right; James Edgemond, our Chief Financial Officer, also to my right; Dr. Betsy Eades, our Head of Business Development, to my left; and also Dewey Steadman, our Head of Investor Relations, also to my left. All 5 of us will be available in the breakout room to answer questions afterwards.

I'd like to start with the safe harbor

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot